EDQM and EMA to clarify how Ph. Eur applies to biosimilars at event next week

By Staff reporter

- Last updated on GMT

EDQM headquarters in Strasbourg, France
EDQM headquarters in Strasbourg, France
The EDQM and EMA aim to clarify how European Pharmacopoeia (Ph. Eur) monographs apply to biosimilars at an event next week.

The event will be held at the European Directorate for the Quality of Medicines’ (EDQM) headquarters in Strasbourg, France on February 8​. 

Delegates – who can attend either in person or online – will be told how the Ph. Eur relates to European Union (EU) regulatory framework for biosimilars. The aim is to make clear the role of monographs and how they should be applied in the biosimilar assessment and approval process.

The event will also feature a presentation on biosimilar quality assessments Niklas Ekman, Senior Researcher (BMWP member), from the Finnish Medicines Agency in Helsinki.

Click here​ for more details.

Related news

Related products

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars